Nature

Markov Chains and Hidden Markov Models

Markov chains provide a fundamental framework for modelling stochastic processes, where the next state depends solely on the current state. Hidden Markov models (HMMs) extend this framework by ...

Markov Chains : The Strange Math That Predicts Almost Anything

Discover how Markov chains predict real systems, from Ulam and von Neumann’s Monte Carlo to PageRank, so you can grasp ...
Nature

Probabilistic Model Checking and Markov Decision Processes

Probabilistic model checking and Markov decision processes (MDPs) form two interlinked branches of formal analysis for systems operating under uncertainty. These techniques offer a mathematical ...
JSTOR Daily

Nonparametric identification and maximum likelihood estimation for hidden Markov models

Nonparametric identification and maximum likelihood estimation for finite-state hidden Markov models are investigated. We obtain identification of the parameters as well as the order of the Markov ...
Thorax

Health economic model to evaluate the cost-effectiveness of smoking cessation services integrated within lung cancer screening in the United Kingdom

Introduction Integrating smoking cessation supports into lung cancer screening can improve abstinence rates. However, healthcare decision-makers need evidence of cost-effectiveness to understand the ...
ascopubs.org

SBRT for early NSCLC: Markov model insight for optimal patient selection.

Attrition bias: Does the benefit of targeted agents (TA) increase the more we search for a selection biomarker? Meta-regression analysis of randomized clinical trials (RCTs) in advanced non-small cell ...
The American Journal of Managed Care

Validation of the FINE-CKD Model for Future Health Technology Assessments for Finerenone in Patients With Chronic Kidney Disease And Type 2 Diabetes

BACKGROUND: The FINE-CKD model was developed to estimate the cost-effectiveness of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). OBJECTIVE: To perform internal ...
ascopubs.org

Cost-effectiveness analysis using a Markov model assessing the addition of bevacizumab to paclitaxel in HER2-negative metastatic breast cancer patients.

Patient-reported pain and other symptoms as prognostic factors for overall survival (OS) in a phase III clinical trial of patients with advanced breast cancer. This is an ASCO Meeting Abstract from ...